Mega Genomics Limited (6667) Stock Statistics & Valuation Metrics

Mega Genomics Limited has a market cap or net worth of HK$1.60B. The enterprise value is HK$995.76M.

Mega Genomics Limited has 224,300,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Mega Genomics Limited’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Mega Genomics Limited is 51.2. Mega Genomics Limited’s PEG ratio is -1.22.

In the last 12 months, Mega Genomics Limited had revenue of 164.23M and earned 45.05M in profits. Earnings per share was 0.22.

In the last 12 months, operating cash flow was 950.88K and capital expenditures -93.14K, giving a free cash flow of 857.74K billion.

Mega Genomics Limited pays an annual dividend of HK$0.17, resulting in a dividend yield of 2.38%

Mega Genomics Limited upcoming earnings date is Apr 1, 2027, TBA (Confirmed).

Mega Genomics Limited as a current ratio of ―, with Debt / Equity ratio of 4.71%

In the past 12 months, Mega Genomics Limited has paid 8.59M in taxes.

Mega Genomics Limited EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Mega Genomics Limited has HK$424.49M in cash and marketable securities with HK$28.52M in debt, giving a net cash position of HK$395.97M billion.

Gross margin is 33.73%, with operating margin of ―, and net profit margin of ―.

The average price target for Mega Genomics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―